BRPI0507675A - derivados de 2'-c-metil nucleosìdeo - Google Patents

derivados de 2'-c-metil nucleosìdeo

Info

Publication number
BRPI0507675A
BRPI0507675A BRPI0507675-7A BRPI0507675A BRPI0507675A BR PI0507675 A BRPI0507675 A BR PI0507675A BR PI0507675 A BRPI0507675 A BR PI0507675A BR PI0507675 A BRPI0507675 A BR PI0507675A
Authority
BR
Brazil
Prior art keywords
nucleoside derivatives
methyl nucleoside
methyl
derivatives
nucleoside
Prior art date
Application number
BRPI0507675-7A
Other languages
English (en)
Portuguese (pt)
Inventor
K Raja Reddy
Mark D Erion
Original Assignee
Merck & Co Inc
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Metabasis Therapeutics Inc filed Critical Merck & Co Inc
Publication of BRPI0507675A publication Critical patent/BRPI0507675A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0507675-7A 2004-02-13 2005-02-14 derivados de 2'-c-metil nucleosìdeo BRPI0507675A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54474304P 2004-02-13 2004-02-13
US10/903,215 US20050182252A1 (en) 2004-02-13 2004-07-29 Novel 2'-C-methyl nucleoside derivatives
PCT/US2005/004447 WO2005084192A2 (en) 2004-02-13 2005-02-14 Novel 2’-c-methyl nucleoside derivatives

Publications (1)

Publication Number Publication Date
BRPI0507675A true BRPI0507675A (pt) 2007-07-17

Family

ID=34841195

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507675-7A BRPI0507675A (pt) 2004-02-13 2005-02-14 derivados de 2'-c-metil nucleosìdeo

Country Status (5)

Country Link
US (4) US20050182252A1 (enExample)
EP (1) EP1720556A4 (enExample)
JP (1) JP2007522237A (enExample)
BR (1) BRPI0507675A (enExample)
WO (1) WO2005084192A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7200970B2 (en) * 2004-02-09 2007-04-10 Trim-Tex, Inc. Combination comprising vertical wall, horizontal ceiling, and crown molding member having planar portion, intermediate portion, and mounting flange
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2006065335A2 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2006104945A2 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
JP2010513484A (ja) * 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CA2673649A1 (en) * 2007-01-05 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
EP2114980B1 (en) 2007-01-12 2012-06-27 BioCryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
KR20110065440A (ko) * 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
AR094621A1 (es) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013106344A1 (en) * 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
US9326991B2 (en) 2012-09-14 2016-05-03 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds and use
US9676809B2 (en) 2013-11-22 2017-06-13 Ligand Pharmaceuticals Incorporated Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections
EP3623364A1 (en) * 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
CN106518942B (zh) * 2016-10-24 2019-04-19 银杏树药业(苏州)有限公司 用于治疗hcv感染的新型环磷酯
US10519186B2 (en) 2017-02-01 2019-12-31 Atea Pharmaceuticals, Inc. Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
KR20200140865A (ko) 2018-04-10 2020-12-16 아테아 파마슈티컬즈, 인크. 간경변증을 갖는 hcv 감염 환자의 치료
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN117500494A (zh) 2021-06-17 2024-02-02 阿堤亚制药公司 有利的抗hcv联合疗法

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL222157A (enExample) * 1956-12-20
US5763596A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
RU2186569C2 (ru) 1996-01-23 2002-08-10 Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах
US6128582A (en) 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
CA2267279A1 (en) 1996-10-16 1998-04-23 Devron Averett Monocyclic l-nucleosides, analogs and uses thereof
CA2266889A1 (en) 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998022458A1 (en) 1996-11-19 1998-05-28 Icn Pharmaceuticals, Inc. Multivalent salts of pyridostigmine and related compounds
KR20000069658A (ko) 1996-12-27 2000-11-25 와트 씨 데이빗, 해리 에이 루스제 Ｇ 풍부 올리고 앱태머 및 면역 반응을 변조시키는 방법
SI9820003A (sl) 1997-01-17 1999-06-30 Icn Pharmaceuticals, Inc. Zdravljenje bolezni povezano s citokini
SE506898C2 (sv) 1997-03-06 1998-02-23 Carlo Castro Ryggsmörjare för insmörjning av hudkräm på en människokropp
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
YU67099A (sh) 1997-06-30 2002-06-19 Icn Pharmaceuticals Inc. Postupak za dobijanje tiazofurina i drugih c-nukleozida
IL121413A (en) 1997-07-28 2000-10-31 Green Cloud Ltd Method for reducing the accumulation of precipitates and impurities on ultrasonic transducers
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
WO1999036074A1 (en) 1998-01-15 1999-07-22 Icn Pharmaceuticals, Inc. Use of 8-cl-camp in prevention of restenosis of arterial walls
US6348587B1 (en) 1998-02-25 2002-02-19 Emory University 2′-Fluoronucleosides
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU767599B2 (en) * 1998-03-06 2003-11-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
JP4690545B2 (ja) 1998-03-31 2011-06-01 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
JP2002516256A (ja) 1998-05-26 2002-06-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 二環式糖成分を有する新規ヌクレオシド
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6045638A (en) 1998-10-09 2000-04-04 Atlantic Research Corporation Monopropellant and propellant compositions including mono and polyaminoguanidine dinitrate
JP2002528499A (ja) 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
PL364699A1 (en) 1999-01-29 2004-12-13 Icn Pharmaceuticals, Inc. Modulation of immune response by ribavirin
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
MXPA02000294A (es) 1999-06-25 2002-06-21 Vertex Pharma Profarmacos de carbamatos inhibidores de impdh.
MXPA02001753A (es) 1999-08-27 2002-10-23 Ribapharm Inc Analogos de nucleosido de pirrolo [2,3-d]pirimidina.
WO2001018013A1 (en) * 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
US6518253B1 (en) 1999-11-19 2003-02-11 Robert Tam Treatment of viral infections using the L-isomer of ribavirin
AU5076601A (en) 1999-12-13 2001-07-03 Icn Pharmaceuticals, Inc. Pulmonary delivery of ribavirin or levovirinTM for systemic and quasi-systemic treatment of disease
JP2003523957A (ja) 1999-12-23 2003-08-12 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド 組成物、並びにｌ−ヌクレオシド、ｌ−ヌクレオチドおよびそれらのアナログの製造法
RU2223761C2 (ru) 1999-12-27 2004-02-20 Джапан Тобакко Инк. Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
US6455508B1 (en) 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
KR100974917B1 (ko) 2000-04-13 2010-08-09 파마셋 인코포레이티드 간염 바이러스 감염 치료를 위한 3'- 또는2'-하이드록시메틸 치환된 뉴클레오시드 유도체
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) * 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2416748A1 (en) 2000-08-22 2002-02-28 Ribapharm Inc. Improved specificity in treatment of diseases
BR0113388A (pt) 2000-08-22 2004-02-25 Ribapharm Inc Métodos de distribuição de drogas a hepatócitos e tratamento de infecções por flaviviridae
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
WO2002020497A1 (en) 2000-09-01 2002-03-14 Shionogi & Co., Ltd. Compounds having anti-hepatitis c virus effect
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
EP1343807B1 (en) 2000-12-12 2009-04-29 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
EP1346724A4 (en) 2000-12-26 2004-11-17 Mitsubishi Pharma Corp AGENT FOR TREATING HEPATITIS C
JP2004532184A (ja) * 2001-01-22 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US20040191214A1 (en) 2001-06-15 2004-09-30 Johnson Lau Nucleoside vaccine adjuvants
GB0119369D0 (en) 2001-08-08 2001-10-03 Bookham Technology Plc Optic system
GB2378524A (en) 2001-08-08 2003-02-12 Bookham Technology Plc Intergrated optic device
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
US20030072451A1 (en) 2001-10-16 2003-04-17 Pimentel Roberto J. Method and apparatus for securely transferring wireless data
WO2003034709A1 (fr) 2001-10-17 2003-04-24 Naltec Inc. Procede de decompression et dispositif de traitement de donnees
WO2003037908A1 (en) 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
AU2002353164A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents
WO2003051899A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2002340387A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Cytidine libraries and compounds synthesized by solid-phase combinatorial strategies
WO2003051881A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
AU2002357876A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Nucleoside analog libraries and compounds
AU2002349905A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Nucleoside libraries and compounds by mcc combinatorial strategies on solid support
US7261704B2 (en) 2001-12-28 2007-08-28 Terumo Kabushiki Kaisha Syringe
EP1572705A2 (en) * 2002-01-17 2005-09-14 Ribapharm, Inc. Sugar modified nucleosides as viral replication inhibitors
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
US7323453B2 (en) * 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
CA2484921A1 (en) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
WO2004037161A2 (en) * 2002-05-13 2004-05-06 Metabasis Therapeutics, Inc. Cyclic prodrugs of pmea one of its analogues
US7193081B2 (en) * 2002-05-13 2007-03-20 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of PMEA and PMPA
EP1572945A2 (en) * 2002-06-27 2005-09-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AP2005003211A0 (en) 2002-06-28 2005-03-31 Idenix Cayman Ltd 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
CA2490191C (en) 2002-06-28 2010-08-03 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
WO2004007512A2 (en) * 2002-07-16 2004-01-22 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004013300A2 (en) 2002-08-01 2004-02-12 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
NZ538457A (en) 2002-09-30 2008-04-30 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
WO2004041837A1 (en) * 2002-10-31 2004-05-21 Metabasis Therapeutics, Inc. Novel cytarabine monophosphate prodrugs
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
TWI294882B (en) * 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
OA13315A (en) 2003-10-14 2007-04-13 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
US7144868B2 (en) * 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP2007509939A (ja) * 2003-10-27 2007-04-19 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染を治療するためのヌクレオシド化合物
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives

Also Published As

Publication number Publication date
US20050182252A1 (en) 2005-08-18
EP1720556A2 (en) 2006-11-15
US20070179114A1 (en) 2007-08-02
US20070042989A1 (en) 2007-02-22
US7666855B2 (en) 2010-02-23
WO2005084192A2 (en) 2005-09-15
US20090131370A1 (en) 2009-05-21
EP1720556A4 (en) 2012-05-09
JP2007522237A (ja) 2007-08-09
WO2005084192A3 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
WO2007022073A3 (en) Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
WO2007029029A3 (en) Tetracyclic indole derivatives as antiviral agents
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
GB0612423D0 (en) Therapeutic agents
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
MA32633B1 (fr) Formes cristallines d'un derive 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc
BR0111569A (pt) Agentes antivirais de imidazopiridina e imidazopirimidina
BRPI0510319A (pt) inibidores da enzima integrase de hiv
BR9909474A (pt) Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
EA200601654A1 (ru) Ингибиторы интегразы вич
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
BR112023000142A2 (pt) Derivados de benzodiazepina úteis no tratamento de infecção pelo vírus sincicial respiratório
WO2006033709A8 (en) Novel nucleoside derivatives
BR0213037A (pt) Derivados de pirimidina
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
BRPI0508079A (pt) composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
NO20021337D0 (no) 4-benzylaminoquinolinkonjugater med gallesyre og deres heteroanaloger, fremgangsmåte for deres fremstilling, legemidlersom inneholder disse forbindelser og deres anvendelse

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.